Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $12.00 target price on the biotechnology company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Price Performance

Shares of DARE stock opened at $3.65 on Thursday. Daré Bioscience has a 1-year low of $3.05 and a 1-year high of $7.56. The stock’s 50-day moving average is $3.41 and its 200 day moving average is $3.95. The company has a market cap of $30.74 million, a P/E ratio of -0.95 and a beta of 1.39.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.60 million. On average, analysts anticipate that Daré Bioscience will post -0.27 EPS for the current year.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC grew its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.